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Synergistic anti-tumor activity and inhibition of
angiogenesis by cotargeting of oncogenic and death
receptor pathways in human melanoma
G Grazia1, C Vegetti1, F Benigni2, I Penna1, V Perotti1, E Tassi1, I Bersani1, G Nicolini1, S Canevari3, C Carlo-Stella4,5, AM Gianni6,
R Mortarini1 and A Anichini*,1
Improving treatment of advanced melanoma may require the development of effective strategies to overcome resistance to
different anti-tumor agents and to counteract relevant pro-tumoral mechanisms in the microenvironment. Here we provide
preclinical evidence that these goals can be achieved in most melanomas, by co-targeting of oncogenic and death receptor
pathways, and independently of their BRAF, NRAS, p53 and PTEN status. In 49 melanoma cell lines, we found independent
susceptibility profiles for response to the MEK1/2 inhibitor AZD6244, the PI3K/mTOR inhibitor BEZ235 and the death receptor
ligand TRAIL, supporting the rationale for their association. Drug interaction analysis indicated that a strong synergistic anti-tumor
activity could be achieved by the three agents and the AZD6244–TRAIL association on 20/21 melanomas, including cell lines
resistant to the inhibitors or to TRAIL. Mechanistically, synergy was explained by enhanced induction of caspase-dependent
apoptosis, mitochondrial depolarization and modulation of key regulators of extrinsic and intrinsic cell death pathways, including
c-FLIP, BIM, BAX, clusterin, Mcl-1 and several IAP family members. Moreover, silencing experiments confirmed the central role of
Apollon downmodulation in promoting the apoptotic response of melanoma cells to the combinatorial treatments. In SCID mice,
the AZD6244–TRAIL association induced significant growth inhibition of a tumor resistant to TRAIL and poorly responsive to
AZD6244, with no detectable adverse events on body weight and tissue histology. Reduction in tumor volume was associated not
only with promotion of tumor apoptosis but also with suppression of the pro-angiogenic molecules HIF1α, VEGFα, IL-8 and TGFβ1
and with inhibition of tumor angiogenesis. These results suggest that synergistic co-targeting of oncogenic and death receptor
pathways can not only overcome melanoma resistance to different anti-tumor agents in vitro but can also promote pro-apoptotic
effects and inhibition of tumor angiogenesis in vivo.
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The development of mutant BRAF (v-raf murine sarcoma viral
oncogene homolog B)- and mitogen/extracellular signal-
regulated kinase (MEK)-specific inhibitors, such as Vemur-
afenib, Dabrafenib and Trametinib, as well as of monoclonal
antibodies targeting immune checkpoints, has markedly
improved the treatment of advanced melanoma, as shown
by highly significant effects, achieved in several trials, on
progression-free and/or overall survival.1–5 However, a frac-
tion of patients does not benefit from target-specific therapy or
immunotherapy, and duration of clinical responses may be
limited.1–5 Mechanisms of resistance to specific inhibitors6
and of tumor escape from immune recognition7 contribute to
prevent induction of melanoma cell death by the new therapies
and explain the urgent need for the identification of more
effective approaches. Different strategies are being investi-
gated to overcome melanoma resistance to single anti-tumor
agents and to rescue tumor susceptibility to cell death,
including co-targeting of constitutively active intracellular
signaling pathways,8–10 association of target-specific drugs
with inhibitors of autophagy or with endoplasmic reticulum-
stress inducers11,12 and association of anti-tumor agents that
trigger the extrinsic and the intrinsic pathway of apoptosis.13–15
The latter approach is based on the combination of specific
inhibitors of main oncogenic pathways, which in different
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tumor types can modulate relevant pro- and anti-apoptotic
molecules in the intrinsic pathway of cell death,16–18 with
targeting of the extrinsic, death receptor-dependent pathway,
by usage of tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) or of agonistic death receptor 5 (DR5)-specific
mAbs.19 Indeed, this approach has shown that association of
MEK, pan-RAF or phosphoinositide 3-kinase (PI3K) inhibitors
with TRAIL can overcome resistance to TRAIL13–15 and can
lead to enhanced melanoma apoptosis in vitro through
different mechanisms, including upregulation of bcl-2-like
protein 11 isoform 1 (Bim) and activation of BCL2-
associated X protein (Bax).13–15 Moreover, as hypothesized
recently by Geserick et al.,20 the association of MEK or pan-
RAF inhibitors with TRAIL could even be exploited as a
potential approach to promote rapid elimination of most tumor
cells, thus preventing the emergence of secondary resistance
to BRAF inhibitors. Furthermore, the interest in the death
receptor pathway, as a therapeutic target, has been recently
strengthened by the evidence that TRAIL mediates disruption
of the tumor-associated vasculature21 and by the discovery of
TIC10, a drug that stimulates production of TRAIL and that
exerts significant anti-tumor activities in preclinical in vivo
models, including aggressive intracranial xenografts of human
glioblastoma cells.22
Nevertheless, it is currently not known whether co-targeting
of MEK and/or PI3K/mammalian target of rapamycin (mTOR)
and of the death receptor pathway inmelanoma can overcome
intrinsic resistance to each of the anti-tumor agents in most
instances, irrespective of the different genetic make-up of the
tumors, and whether this approach can exert synergistic,
rather than additive, anti-melanoma effects. Furthermore, it
remains to be verified whether the combination of MEK or
PI3K/mTOR inhibitors with death receptor agonists (such as
TRAIL itself or DR5-specific mAbs) may also exert significant
pro-apoptotic effects in vivo on melanoma xenografts and
whether this is associated with inhibition of relevant pro-
tumoral processes in the tumor microenvironment.
To address these issues, in this study we evaluated the anti-
melanoma activity in vitro and in vivo of two- or three-drug
associations using TRAIL, the MEK 1/2 inhibitor AZD6244/
Selumetinib, which has significant clinical activity in
melanoma,23 and the PI3K/mTOR inhibitor BEZ235, currently
in clinical trials in different solid tumors, including melanoma
(source www.clinicaltrials.gov). The results indicated that the
three-agent (AZD6244/BEZ235/TRAIL) and two-agent
(AZD6244/TRAIL) combinations exerted synergistic pro-
apoptotic effects on most melanomas in a large panel. These
results were observed even on melanoma cell lines resistant
to TRAIL or to the inhibitors and independently of their BRAF,
neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS),
p53 and phosphatase and tensin homolog (PTEN) status.
Moreover, an in vivo model showed that the AZD6244/TRAIL
association promoted melanoma apoptosis associated with
marked inhibition of angiogenesis.
Results
Independent susceptibility profiles to target-specific
inhibitors and TRAIL in human melanomas. We asked
whether concomitant resistance to MEK, PI3K/mTOR inhibi-
tors and to the death receptor ligand TRAIL is frequent in
human melanoma. To this end, a panel of 49 melanoma cell
lines (Supplementary Table S1), with known BRAF, NRAS,
PTEN and p53 status, was characterized for susceptibility to
AZD6244, BEZ235 and TRAIL. Several lines responsive
(IC50o0.05 μM) to AZD6244 or BEZ235 were TRAIL resis-
tant (o10% dead cells at TRAIL 100 ng/ml), whereas a
number of cell lines resistant to these inhibitors (IC50≥0.2
μM) showed good susceptibility to TRAIL (representative data
in Figure 1a). Spearman analysis of raw data shown in
Supplementary Table S1 indicated no significant correlation
between susceptibility to the inhibitors and to TRAIL
(Figure 1b). Indeed, concomitant resistance to AZD6244
and TRAIL or to BEZ235 and TRAIL was found in only 7 and
10 cell lines, respectively (marked by open circles and
squares, Figure 1b), supporting the rationale for association
of these anti-tumor agents. We then found that response to
TRAIL correlated significantly not only with caspase-8
cleavage (P= 0.0086) but even with mitochondrial depolar-
ization (Po0.0001, Figure 1b and Supplementary Table S1),
in agreement with the notion that melanoma cells behave as
type II cells in response to TRAIL, requiring activation of the
intrinsic pathway of cell death.24 This latter finding provided
also a mechanistic rationale for the co-targeting of oncogenic
and death receptor pathways. In fact, TRAIL triggers the
extrinsic pathway of apoptosis, while inhibitors, such as
AZD6244 or BEZ235, can promote cell death by modulating
pro- and anti-apoptotic molecules in the intrinsic pathway of
cell death.16–18
In addition, TRAIL-R1 (DR4) and TRAIL-R2 (DR5) were
always expressed in vitro, although with different staining
intensity (Supplementary Figure S1a), and the levels of
expression of DR5 correlated significantly with responsive-
ness to TRAIL, indicating the relevance of such receptor
(Supplementary Figure S1a). In vivo TRAIL-R2/DR5 expres-
sion was confirmed in neoplastic cells from melanoma
metastases (Supplementary Figure S1b), supporting the
choice of targeting this pathway in melanoma.
Co-targeting of oncogenic and death receptor pathways
exerts synergistic anti-tumor effects in most melanomas,
irrespective of genetic background, and overcomes
resistance to each agent. Melanoma cell lines susceptible
to AZD6244, BEZ235 and TRAIL (Me1 and Me83) or
resistant to TRAIL and poorly responsive to AZD6244
(Me13 and Me6) were selected for drug interaction analysis.
All possible two- and three-drug combinations were evaluated
by the Chou and Talalay method.25 Outcome of drug
interaction, in terms of synergism/antagonism and of fraction
affected (FA) values, was markedly dependent on the
specificity of the combination and on dosing of each agent,
as indicated by FA versus Combination Index (CI) plots
(Supplementary Figure S2a). However, the AZD6244–
BEZ235–TRAIL and the AZD6244–TRAIL combinations
could achieve strong synergism (CIo0.3), with high FA
values, in all four cell lines, and the lowest CI values were
observed when AZD6244 was used at 0.05 μM (asterisks,
Supplementary Figure S2a). Western blotting analysis
confirmed effective inhibition of P-ERK, by AZD6244, and
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Figure 1 Independent susceptibility profiles of melanoma cells to MEK, PI3K/mTOR inhibitors and TRAIL. (a) Responsiveness of selected melanoma cell lines to AZD6244,
BEZ235 and TRAIL, by MTTassay. (b) Cell viability (by MTTassay), mitochondrial depolarization (by TMRE assay) and caspase-8 cleavage (by flow cytometry) in response to
TRAIL (100 ng/ml, 48 h) shown by a color code indicating the ratio of the values for each tumor to the median value of each parameter in the whole panel of cell lines.
Responsiveness to AZD6244 and BEZ235 (by MTTassay, 48 h) shown by a color code indicating the log-transformed ratio of the IC50 of each tumor to the median IC50 of each
inhibitor in the whole panel. Data clustered by the three parameters in response to TRAIL. Statistical analysis by Spearman correlation analysis. TRAIL-resistant melanoma cell
lines with IC50 to AZD6244 (○) or to BEZ235 (□)40.2 μM
MEK, PI3K/mTOR inhibitors and TRAIL in melanoma
G Grazia et al
3
Cell Death and Disease
of P-AKT by BEZ235 in different melanoma cell lines
(Supplementary Figure S3).
Drug interaction analysiswas then extended to a panel of 21
melanoma cell lines with distinct susceptibility profiles to the
inhibitors and TRAIL. Analysis of the AZD6244–BEZ235–
TRAIL combinatorial treatment confirmed a strong synergistic
interaction with CIo0.3 and high levels of FA in all AZD6244-
resistant lines (n=7) and in 13/14 AZD6244-susceptible lines,
when AZD6244 was used at 0.05 μM, irrespective of TRAIL
and BEZ235 concentrations (Figure 2a). In contrast, strong
antagonism emerged frequently in most lines at [AZD6244]
o0.05 μM and at [BEZ235]o0.02 μM (Supplementary Figure
S4a). At the most effective AZD6244 dosing, the synergism
between target-specific inhibitors and TRAIL was observed
not only in cell lines resistant to AZD6244 but even in those
with high IC50 values to BEZ235, or completely resistant to
TRAIL, and irrespective of BRAF, NRAS, p53 and PTEN status
(Figure 2, right hand table). Moreover, increasing doses of
BEZ235 and of TRAIL were associated with further improve-
ment in either CI (Figure 2a) or FA values (Supplementary
Figure S5 for box and whiskers plots of FA data). Detailed
statistical analysis of FA data (Supplementary Table S2)
indicated that significant increase of FA values could be
observed when: (a) TRAIL was used at the highest dose
(25 ng/ml) in the AZD6244–BEZ235–TRAIL combination
compared with 5 and 10 ng/ml; (b) adding BEZ235 to the
AZD–TRAIL association; (c) adding TRAIL to the AZD6244–
BEZ235 association. In the same panel of cell lines, strong
synergism could be observed even by the AZD6244–TRAIL
combination, again when AZD6244 was used at 0.05 μM
(Figure 2b, for [TRAIL]= 25 ng/ml, and Supplementary Figure
S4b, for [TRAIL]=5 or 10 ng/ml and Supplementary Figure
S6a for box and whiskers plot of FA data). In contrast, the
BEZ235-TRAIL combinatorial treatment showed marked
antagonism and poor fraction affected at in most instances
(Figure 2c for [TRAIL]= 25 ng/ml, Supplementary Figure S4c,
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Figure 2 Synergistic anti-tumor interaction of AZD6244-BEZ235-TRAIL and AZD6244-TRAIL combinations but not of BEZ-TRAIL association in melanoma cells. Drug
interaction analysis by Chou and Talalay method in two groups of melanoma cell lines with different responsiveness to AZD6244 (resistant lines: IC50≥ 0.2 μM, n= 7; susceptible
lines: IC50≤ 0.2 μM, n= 14) treated with the association of (a) AZD6244, BEZ235 and TRAIL or (b) AZD6244 and TRAIL or (c) BEZ235 and TRAIL. Combination indexes
(CI, upper panel), and fraction affected (FA, lower panel) by a color code shown in the lower right hand side of the figure. Red indicates antagonism while green indicates synergy,
as shown in Supplementary Figure S2b. Susceptibility to TRAIL, AZD6244 and BEZ235 and main molecular features of all cell lines summarized in the right hand side panel
(m: mutant; wt: wild type; +,− : expression/lack of expression of PTEN by western blotting). Numbers at the bottom of the upper and lower panels: median CI values and mean FA
values, respectively, for each combination of drugs and TRAIL doses
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for [TRAIL]=5 or 10 ng/ml and Supplementary Figure S6b for
box and whiskers plot of FA data). Synergistic interaction of
AZD6244–BEZ235–TRAIL and AZD6244–TRAIL associa-
tions was confirmed also in melanoma cells freshly isolated
from surgical samples (data not shown). Taken together, these
results indicated that association of MEK and PI3K/mTOR
inhibitors with TRAIL, or MEK blockade with TRAIL, leads to
synergistic anti-tumor effects on most melanoma cell lines,
even on inhibitor- or TRAIL-resistant ones.
Combinatorial treatments rescue susceptibility of
melanoma cells to caspase-dependent apoptosis. To
uncover the main biological processes behind the synergistic
interactions, we carried out whole genome gene expression
analysis of Me13 cells, resistant to TRAIL and poorly
responsive to AZD6244, upon treatment with inhibitors and
TRAIL. Genes significantly modulated by the AZD6244–
BEZ235–TRAIL association, identified by class comparison
and visualized by Edwards-VENN diagrams (light blue circles
in Supplementary Figure S7a),26 were subjected to down-
stream effects analysis. Significant upregulation of the
functions ‘cell death’ and ‘apoptosis’ and downregulation of
the functions ‘tumorigenesis’, ‘cell migration’ and ‘prolifera-
tion’ (Supplementary Figure S7b and Supplementary Table
S3) were identified. Analysis of genes modulated by the
AZD6244–TRAIL association confirmed enhancement of the
functions ‘cell death’ and ‘apoptosis’ (Supplementary Figures
S8a and b and Supplementary Table S4). By annexin-V/PI
flow cytometry assays (Figure 3a), significantly higher levels
of apoptosis, compared with single agents, were observed in
5/8 cell lines by AZD6244–TRAIL or by BEZ235–TRAIL
treatments (Po0.01 by analysis of variance (ANOVA)
followed by Student–Newman–Keul (SNK) test) and in 8/8
cell lines by the AZD6244–BEZ235–TRAIL combination
(Po0.01 in 7/8 lines and Po0.05 in 1/8 lines). Enhanced
melanoma apoptosis (Supplementary Figure S9) was also
observed by the association of inhibitors with membrane-
bound TRAIL,27 as well as when TRAIL was associated with
different MEK (PD0325901) and mTOR (rapamycin) inhibi-
tors (Supplementary Figure S10).
Caspase activation assays indicated significant activation of
caspase 3/7, by AZD6244–BEZ235–TRAIL and AZD6244–
TRAIL combinations, compared with single agents (Po0.01)
and to AZD6244–BEZ235 (Po0.01, Figure 3b), as well as of
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Figure 3 Combinatorial treatments promote caspase-dependent melanoma apoptosis. (a) Melanoma cells were treated with AZD6244 (0.05 μM), BEZ235 (0.05 μM) and
TRAIL (25 ng/ml) and their combinations for 72 h, and apoptosis was assessed by Annexin-V/PI assay. Results shown as sum of early (annexin-V+ PI−) and late (annexin-V+ PI+)
apoptosis values. (b) caspase 3/7 activation in two melanoma cell lines treated as in panel (a) but assessed at 24 h. (c and d) Annexin-V/PI assays ((c), single experiment; (d),
average of three experiments) in melanoma cells (Me 5, Me13) treated as in panel (a), in the presence of the pancaspase inhibitor z-VAD-fmk or of the negative control peptide
z-FA-fmk. (a, b, d), Mean values (± S.D.) for three independent experiments; (d), statistical analysis by ANOVA followed by SNK test. ***Po0.001, **Po0.01; *Po0.05
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caspase-8 and 9 (data not shown). A pan caspase inhibitor
(z-vad-fmk) completely abolished the increase in apoptosis
induced by the addition of TRAIL to the AZD6244–BEZ235
combination, even in TRAIL-resistant (Me13) or in weakly
susceptible (Me5) melanomas, but did not impact on cell death
promoted by the AZD6244–BEZ235 combination (Figures 3c
and d). Similar results were observed by the AZD6244–TRAIL
combinatorial treatment (Supplementary Figure S11). Taken
together, these results indicated that co-targeting of MEK and
PI3K/mTOR pathways and of the death receptor pathway
has synergistic anti-melanoma activity likely mediated by
enhanced induction of caspase-dependent apoptosis.
Pro- and anti-apoptotic molecules in the extrinsic
and intrinsic apoptosis pathways are modulated by
combinatorial treatments. To gain insight into the mechan-
isms leading to enhanced activation of caspase-dependent
apoptosis, we tested whether combinatorial treatments
affected expression of pro- and anti-apoptotic molecules in
the extrinsic and intrinsic pathways of cell death. Western
blotting analysis indicated that the AZD6244–BEZ235–TRAIL
combination induced the most marked downregulation of the
caspase-8 inhibitor c-FLICE-like inhibitory protein (c-FLIP),
with effects seen on both c-FLIPL and/or c-FLIPS (Figure 4a).
This occurred not only in Me41, partially responsive to TRAIL
and susceptible to the inhibitors but also in Me13 cells, poorly
responsive to AZD6244 and resistant to TRAIL. The same
association induced significant caspase-8 cleavage (Figures
4b and c). The efficacy of this combinatorial treatment was
documented also by analysis of Bcl-2 family members:
upregulation of the pro-apoptotic isoforms BIMS and
BAXα,28,29 downregulation of two isoforms (ps and s) of the
Bax inhibitor clusterin30 (Figure 4d), and downmodulation of
myeloid cell leukemia 1 (Mcl-1) (Supplementary Figure S12)
and BH3 interacting domain death agonist (BID) (data not
shown) were found. In agreement with the known role of
these Bcl-2 family members in the mitochondrial pathway of
cell death,31 the AZD6244–BEZ235–TRAIL combination also
promoted the strongest increase in mitochondrial depolariza-
tion compared with single agents and to the AZD6244–
BEZ235 combination (Figures 4e and f). Enhanced modula-
tion of c-FLIP, and upregulation of BIMS and BAXα, but not of
clusterin, compared with single agents (Supplementary
Figures S13a and b), as well as caspase-8 cleavage
and mitochondrial depolarization (Supplementary Figures
S13c and d) were confirmed also for the AZD6244–TRAIL
association.
We then assessed the potential role of several X-linked
inhibitor of apoptosis (IAP) family members. Treatment of two
melanoma cell lines (Me13 and Me41) with the AZD6244–
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Figure 4 Modulation of pro- and anti-apoptotic molecules by melanoma treatment with target-specific inhibitors, TRAIL and their combination. (a) Western blotting analysis for
c-FLIP expression and (b) flow cytometry analysis for cleaved caspase-8 in two melanoma cell lines (Me13 and Me41) treated with AZD6244 (A), BEZ235 (B), TRAIL (T) or the
indicated combinations. (c) Cleaved caspase-8 analysis in a panel of nine cell lines. (d) Western blotting analysis for expression of BIM, clusterin and BAX in Me13 cells treated as
in panel (a). (e) TMRE analysis for mitochondrial depolarization in two melanoma cell lines (Me 13 and Me 41) treated as in panel (a). (f) TMRE assay in a panel of six melanoma
cell lines. The numbers in flow cytometry panels in (b) and (e) indicate the percentage of caspase-8+ cells and the percentage of TMRE− cells, respectively. Statistical analysis in
panels (c and f) by ANOVA followed by SNK test; ***Po0.001
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BEZ235–TRAIL combination induced strong downmodulation
of c-IAP1, c-IAP2, XIAPand Apollon comparedwith the effects
of single agents and to AZD6244–BEZ235 treatment
(Figure 5a). Similarly, the AZD6244–TRAIL association was
more effective than single agents in downmodulating these
IAPs (Supplementary Figure S14). The giant IAPApollon was
recently shown by us to have a relevant role in suppressing
melanoma response to MEK inhibitors and to TRAIL.27
Silencing experiments, by previously validated siRNA,27
confirmed the central role of Apollon downmodulation in
promoting the apoptotic response of melanoma cells even to
these combinatorial treatments. In cells treated with TRAIL
only, or with AZD6244-BEZ235, Apollon silencing led
to mitochondrial depolarization (Figure 5b) and apoptosis
levels (Figure 5c) similar to those found in cells treated
with the AZD6244–TRAIL or the AZD6244–BEZ235–TRAIL
combination.
Taken together, these results suggest that association of
TRAIL with co-targeting of MEK and PI3K/mTOR, or with MEK
blockade only, promotes effective melanoma cell death by
modulating key molecules involved in regulation of both the
extrinsic and intrinsic apoptosis pathways.
Co-targeting of MEK and death receptor pathways has
anti-tumor activity in vivo by promotion of melanoma cell
death and inhibition of angiogenesis. Our goal was then
to verify whether co-targeting of oncogenic and death
receptor pathways could exert significant anti-tumor effects
in vivo and whether such activity was associated with effects
on the tumor microenvironment. To this end, we decided to
investigate the effects of treatment with AZD6244 and TRAIL,
as both the three-drug (AZD/BEZ/TRAIL) and two-drug (AZD/
TRAIL) associations shared synergistic anti-tumor activity
in vitro and similar mechanisms of promotion of apoptosis.
Downstream effect analysis on the set of genes modulated
by the AZD6244–TRAIL association (Supplementary Figure
S8a) showed evidence for inhibition of functions associated
with migration and proliferation of endothelial cells
(Supplementary Figure S8b and Supplementary Table S4),
in addition to upregulation of the functions ‘cell death and
apoptosis’. Upstream regulator analysis predicted a highly
significant inhibition of several angiogenesis-related master
regulators, including transforming growth factor β1 (TGFβ1),
hepatocyte growth factor, epidermal growth factor, v-myc
avian myelocytomatosis viral oncogene homolog (Myc),
hypoxia inducible factor 1 alpha subunit (HIF1α) and vascular
endothelial growth factor alpha (VEGFα) (Supplementary
Table S5), in addition to microphthalmia-associated transcrip-
tion factor activation, an expected effect of extracellular signal-
regulated kinase (ERK) pathway inhibition.32 Protein array
experiments on Me13 cells confirmed strong downmodulation
of several angiogenesis-related molecules by the AZD6244-
TRAIL association, compared with untreated or to AZD6244-
treated cells (Supplementary Figure S15). Western blotting
analysis showed a decrease in Myc and HIF1α levels upon
treatment of Me13 cells with AZD6244–TRAIL or with
AZD6244 only (Supplementary Figure S16a). Overnight
treatment of melanoma cells with AZD6244–TRAIL led
to a more pronounced suppression of VEGFα and
TGFβ1 secretion, compared with the effects induced by
AZD6244 alone (Supplementary Figure S16b). Control
apoptosis assays indicated that the inhibitory effect by
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Figure 5 Modulation of IAP proteins and role of Apollon in the response of melanoma to the combination of target-specific inhibitors and TRAIL. (a) Modulation of IAP proteins
by treatment of two melanoma cells lines (Me13 and Me41) with AZD6244 (A), BEZ235 (B) TRAIL (T) and their combinations (AB, ABT); NT: untreated. (b and c) Effect of Apollon
silencing on mitochondrial depolarization (b) and cell death (c) in Me41 cells treated with the indicated agents and their combinations. (b and c) Mean values (± S.D.) for three
independent experiments; statistical analysis in panels (b and c) by ANOVA followed by SNK test; ***Po0.001. **Po0.01. *Po0.05. NS, not significant
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AZD6244–TRAIL treatment on VEGFα secretion at 18 h was
not explained by induction of melanoma cell death
(Supplementary Figure S16c). Moreover, significant inhibition
of VEGFα secretion by overnight AZD6244–TRAIL treatment
was confirmed in 4 out of the 5 additional melanoma cell lines
(Supplementary Figure S16d).
Based on this preliminary in vitro evidence, we then
selected a tumor (Me13) resistant to TRAIL and poorly
responsive to AZD6244 for in vivo experiments. AZD6244
treatment of severe combined immunodeficiency (SCID)mice,
bearing s.c. Me13 xenografts, exerted a moderate but
significant tumor inhibition effect, while TRAIL had no impact
on tumor growth (Figure 6a). However, the AZD6244–TRAIL
combination showed a highly significant anti-tumor activity
compared not only with TRAIL treatment but also with
AZD6244 (Figure 6a). Histological analysis of main organs
(Supplementary Figure S17a) and monitoring of mice weight
(Supplementary Figure S17b) did not indicate any significant
toxicity associated with these treatments. Melanoma cells
from neoplastic nodules removed at the end of treatment
showed enhanced positivity for terminal deoxynucleotidyl
transferase-mediated dUTP nick end-labeling (TUNEL) and
cleaved caspase 3, associated with downmodulation of
P-ERK and Apollon, in animals treated with the AZD6244–
TRAIL association, compared with single treatments
(Figure 6b). These results were consistent with effective
inhibition of the ERK pathway and with promotion of
melanoma cell death. In addition, the AZD6244–TRAIL
combination was more effective than AZD6244 treatment in
reducing the expression in vivo, in neoplastic cells, of HIF1α,
VEGFα and even of interleukin8, a well-known pro-angiogenic
target of HIF-1α (Figure 7a). Most importantly, neoplastic
nodules from animals treated with the AZD6244–TRAIL
association showed a markedly reduced density of both large
and small blood vessels, as assessed, respectively, by
analysis of very wide microscopy fields on hematoxylin and
eosin-stained sections (Figure 7b) and by staining for murine
CD31 endothelial cell marker (Figure 7c).
Taken together, these results indicate that a combinatorial
treatment approach that targets at least one relevant
melanoma survival pathway (MEK–ERK) and the TRAIL
signaling pathway has significant anti-tumor activity in vivo
even against a tumor poorly responsive to a MEK inhibitor and
completely resistant to TRAIL. Moreover, these results
indicate that this strategy acts by both direct anti-tumor effects
and by inhibition of angiogenesis.
Discussion
The results of this study indicate that co-targeting of oncogenic
and death receptor pathways in melanoma exerts synergistic
anti-tumor effects through a direct induction of cell death, by
promotion of caspase-dependent apoptosis and through an
indirect activity on tumor vasculature. The two effective
combinatorial treatments (AZD6244–BEZ235–TRAIL and
AZD–TRAIL) were shown to overcome resistance to each
agent, and the synergistic drug interaction effects were
observed on melanoma cell lines with different genetic
background, including mutations of BRAF or NRAS, as well
as mutations of p53 and/or PTEN, two genes whose
inactivation contributes to melanoma resistance to target
therapy.33,34 In contrast, the third combinatorial treatment that
we investigated (BEZ235–TRAIL) was characterized by
marked antagonism and poor fraction affected in most
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(a) Female SCID mice (n= 7/group) bearing Me13 xenografts were treated between day 11 and day 25 (dotted line) with AZD6244, TRAIL or their combination. Statistical
analysis by mixed models ANOVA; ****Po0.0001; **Po0.01. (b) Immunohistochemistry analysis of tumor nodules removed from control and treated mice. Insets, higher
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instances, suggesting that inhibition of the PI3K/mTOR
pathway can have synergistic anti-melanoma effects with
TRAIL only when associated with targeting of the MEK–ERK
pathway.
Gene expression experiments coupled to in vitro cell death
assays indicated that the anti-tumor effects of the three- and
two-drug associations were due to promotion of caspase-
dependent melanoma cell death. This observation suggested
that the combinatorial treatments could effectively counteract
distinct apoptosis resistance mechanisms that hinder mela-
noma response to monotherapy based on TRAIL or target-
specific inhibitors.9,35–37 This hypothesis was confirmed by
investigation of several components of the extrinsic and
intrinsic pathways of apoptosis. c-FLIP, the main caspase-8
inhibitor, is overexpressed in melanoma lesions38 and is a
main mechanism of melanoma resistance to TRAIL, as
indicated by studies where c-FLIP downregulation was
sufficient to render TRAIL-R2+ melanoma cells responsive to
this death ligand.39 We found that both the AZD6244–
BEZ235–TRAIL and the AZD6244–TRAIL combinations
induced strong downmodulation of c-FLIPL and/or c-FLIPs
isoforms, associated with caspase-8 activation, compared
with single treatments and to the AZD6244–BEZ235 treat-
ment. Moreover, we hypothesized that rescuing the activation
of caspase-8 could not be sufficient to explain the overall
pro-apoptotic efficacy of the combinatorial treatments but that
additional effects on the mitochondrial pathway were likely to
occur. In agreement with this hypothesis, we found that
co-targeting of oncogenic and death receptor pathways
promoted a strong upregulation of pro-apoptotic BIMS and
BAXα isoforms, associated with downregulation of clusterin
and of Mcl-1. Interestingly, BIM has been recently shown to
activate BAX,40 while clusterin is a known inhibitor of the pro-
apoptotic activity of BAX.30 Moreover, BIM mediates the
apoptotic response to AZD6244 in diffuse large B cell
lymphoma16 and to BEZ235 in KRAS-mutant colorectal
cancer cells,41 while BIMS upregulation has a key role in
melanoma apoptosis induced by BRAFV600E inhibitors.29
Taken together, our results suggest that association of TRAIL
with co-targeting of MEK and PI3K/mTOR, or with MEK
blockade, triggers a BIM–BAX axis, thus effectively contribut-
ing to promotion of mitochondrial depolarization.
We also found that the AZD6244–BEZ235–TRAIL and
AZD6244–TRAIL associations influenced the expression of
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several IAP family members. Overexpression of these proteins
contributes to apoptosis resistance in different tumors,
including melanoma,27,42 by inhibition of both initiator and
effector caspases.43 Interestingly, we found that the combina-
torial treatments induced a strong downmodulation of c-IAP1,
c-IAP2, XIAP and Apollon, and this may contribute to explain
the significant activation of caspase-3/7 that we observed.
Moreover, the key role of IAP downmodulation, in the pro-
apoptotic effects of the combinatorial treatments, was con-
firmed by silencing of Apollon, a IAP whose role in melanoma
resistance to a wide range of pro-apoptotic agents we have
recently demonstrated.27
The available evidence on the mechanisms of action,
in vivo, of TRAIL and inhibitors as AZD624421,44,45 led us to
hypothesize that their association might have anti-tumor
effects not only uniquely exerted through induction of
apoptosis but also through inhibition of angiogenesis. Indeed,
in SCIDmice bearing s.c. melanoma xenografts, we found that
the AZD6244–TRAIL association exerted a significant anti-
tumor activity, compared with single treatments, in a TRAIL-
resistant tumor. The combinatorial treatment suppressed not
only several pro-angiogenic molecules and, in vivo, promoted
melanoma apoptosis, but also significantly affected tumor
angiogenesis. The inhibitory effects of AZD6244–TRAIL
treatment on master regulators of angiogenesis, such as
TGFβ1, HIF1α and Myc, as well as on production of
angiogenic molecules as VEGFα, were observed at a time
(8–18 h of treatment) when no significant melanoma cell death
was yet induced, suggesting that the observed anti-
angiogenic effect was not simply explained by increased
melanoma apoptosis. Moreover, inhibition of the main
angiogenesis regulator VEGFα by AZD–TRAIL treatment
was observed in several melanoma cell lines, suggesting that
this is a general effect of this combinatorial treatment.
In conclusion, the results of this study provide a proof
of principle for future combinatorial approaches to
melanoma therapy that may overcome intrinsic resistance
to single agents46 and exert relevant effects on the tumor
microenvironment.
Materials and Methods
Melanoma cell lines. Melanoma cell lines were established as described47,48
from surgical specimens of American Joint Committee on Cancer Stage IIIb to IV
melanoma patients not previously subjected to chemotherapy and admitted to
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan. All lesions were
histologically confirmed to be cutaneous malignant melanomas. The study was
conducted according to the Declaration of Helsinki Principles and following
institutional guidelines. Molecular and biological features of the cell lines, including
susceptibility to TRAIL and to target-specific inhibitors, are listed in Supplementary
Table S1. Methods for identification of mutations in BRAF, NRAS, PTEN and p53
genes and main molecular features of the cell lines have been previously
reported.27,42,48,49 All cell lines were maintained as described.47
Treatment of melanoma cells with inhibitors or TRAIL. Cells were
treated with different concentrations of AZD6244 (SelleckChem, Houston, TX, USA),
BEZ235 (SelleckChem), recombinant human TRAIL (AdipoGen, San Diego, CA,
USA) or with combinations of these agents. Treatments were performed in
quadruplicates in 96-well flat bottom plates with 200 μl RPMI 1640 (BioWhittaker,
VWR International, Radnor, PA, USA) supplemented with 2% fetal calf serum
without antibiotics. Cultures were evaluated at 48–72 h as described27,42 for cell
viability, by the 3-(4,5)dimethylthiazol-2,5-diphenyltetrazolium bromide (MTT) assay.
IC50 values for melanoma response to AZD6244 and BEZ235 were obtained
through nonlinear regression analysis (by the PRISM software, Graphpad, La Jolla,
CA, USA) of dose–response curves. Data from MTTassays were analyzed for drug
interaction by the Chou and Talalay method.25 Combination indexes and FA values
were obtained by the CompuSyn software (ComboSyn Inc., Paramus, NJ, USA).
Antibodies for flow cytometry and western blotting analysis.
Flow cytometry and/or western blottig analyses were carried out with antibodies
specific for: cleaved caspase 8, livin, clusterin, cIAP-2, BIM, BID, BAX, Mcl-1 and
c-Myc (Cell Signaling Technology Inc., Danvers, MA, USA); survivin (Novus
Biological, Littleton, CO, USA); c-IAP1 (R&D Systems, Minnneapolis, MN, USA);
HIF1α and β-actin (Abcam, Cambridge, UK); Apollon/BIRC6 and XIAP (BD
Biosciences, Franklin Lakes, NJ, USA); cFLIPL/S (Alexis Biochemicals, Enzo Life
Sciences Inc., Farmingdale, NY, USA); PE-TRAIL-R1/DR4, PE-TRAIL-R2/DR5
(BioLegend, San Diego, CA, USA); and TRAIL-R3/DCR1 and TRAIL-R4/DCR2
(AdipoGen).
Flow cytometry assays. Melanoma apoptosis was assessed by the Annexin
V/PI flow cytometry assay as described.27 Expression of intracellular molecules was
evaluated by flow cytometry after cell permeabilization with saponin or methanol, as
described.47 Mitochondrial membrane depolarization was assessed by the fluorescent
probe tetramethyl rhodamine ethyl ester (TMRE; Invitrogen, Life Technologies, Grand
Island, NY, USA) as described. 27 Flow cytometry experiments were carried out with a
Gallios flow cytometer (Beckman Coulter, Inc., Brea, CA, USA). All data were analyzed
with the FlowJo software (FlowJo LLC, Ashland, OR, USA).
Western blots. SDS-PAGE was performed using 30–60 μg of protein samples
on 7% NuPAGE Tris-Acetate (for Apollon) or 4–12% NuPAGE Bis-Tris
polyacrylamide gels (Invitrogen, Life Technologies), as described.27,49 Development
was performed by the chemiluminescence method with the ECL Western Blotting
Detection System (GE Healthcare, Fairfield, CT, USA).
Apoptosis and angiogenesis protein arrays. The Human Angiogen-
esis Array kit (R&D Systems) was used according to the manufacturer’s instructions.
Signals on membranes were detected by chemiluminescence and quantitated by
densitometric analysis with Quantity One software (Bio-Rad Laboratories Inc.,
Hercules, CA, USA). Protein expression values were expressed as the percentage
of the mean of the relative positive controls, after background subtraction.
Genome-wide expression profiling of melanoma cells treated
with target-specific inhibitors and TRAIL. Melanoma cells were treated
with AZD6244 (0.1 μM), BEZ235 (0.1 μM) or TRAIL (25 ng/ml) or with their
combinations for 8 h. Three biological replicates for each treatment were set up.
RNA isolation and processing were performed as described.27 Single-color
hybridization of RNAs was performed on Illumina Bead Chip HumanHT-12_v4
Microarrays (Illumina, San Diego, CA, USA) containing448 000 transcript probes.
The expression profiles have been deposited in NCBI’s Gene Expression Omnibus
(GEO) with GSE accession number GSE55050. Background correction, filtering of
data and quantile normalization were done using the BeadStudio Illumina software.
Identification of significantly modulated genes (by BRB array tools vers. 4.3.0),
generation of Edwards-VENN diagrams (by the VENNTURE software26) and
downstream effects analysis and upstream regulator analysis (by Ingenuity Pathway
Analysis, IPA 8.5, www.ingenuity.com) were carried out as described in
Supplementary Methods.
Enzymatic activity of caspases and treatment of melanoma cells
with caspase inhibitors. Caspase 3/7 activation was evaluated by the MUSE
caspase 3/7 kit, specific for the MUSE cell analyzer (Merck Millipore, Billerica,
MA, USA). Where mentioned, melanoma cells were preincubated with general
caspase inhibitor z-VAD-fmk or control z-FA-fmk (BD Pharmingen, Franklin Lakes,
NJ, USA) at 5 μM for 1 h at 37 °C before treatment with drugs. Apoptosis was then
assessed by the annexin-V/PI flow cytometry assay.
Silencing of Apollon by small interfering RNA (siRNA). Cells were
transfected with one of the two previously validated27 Apollon-specific siRNA
(Stealth RNAi siRNA, sequence 5′-GGGCAUGCUGGAAUGUUGACGUUAA-3′,
Invitrogen) and corresponding negative control siRNAs according to Lipofectamine
RNAiMAX guidelines (Invitrogen) to reach a final siRNA concentration of 75 nmol/l.
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ELISA. The Quantikine ELISA kit (R&D Systems) for TGFβ1 and VEGFα were
used according to the manufacturer’s instructions. The optical density of each plate
was determined using a microplate reader (Infinite M1000, Tecan Group Ltd.,
Männedorf, Switzerland).
In vivo treatments. Animal experiments were performed according to the
Italian laws (D.L. 116/92 and after additions) and were approved by the institutional
Ethical Committee for Animal Experimentation of our Institute and by the Italian
Ministry of Health (Project INT_17/2011). Female SCID mice 8–10-weeks old
(Charles River Laboratories, Wilmington, MA, USA) were provided with food and
water ad libitum. Melanoma cells (Me13) were harvested in exponential growth
phase and were injected subcutaneously (5 × 106) in the left flank of each mouse.
When tumors became palpable, mice were randomized into four groups (7 animals/
group). Animals received either vehicle, 25 mg/kg AZD6244 (oral gavage), 30 mg/kg
TRAIL (i.p. injection) or a combination of the two drugs, 7 days per week for 2
consecutive weeks. Mice were monitored daily for signs of toxicity and were
weighed twice weekly. Tumor size was regularly evaluated by measuring the ortho-
gonal diameters (d and D) and calculating the volumes with the following formula:
4
3
p
d2D
2
Immunohistochemistry. Immunohistochemistry was performed on formalin-
fixed, paraffin-embedded tissues as described.27,42,47 Tissue sections from melanoma
metastases were characterized by staining for TRAIL-R2/DR5 (Sigma-Aldrich,
St. Louis, MO, USA). Neoplastic nodules removed from SCID mice at the end of
treatment were characterized by staining with mAbs to human pERK, cleaved
caspase-3 (Cell Signaling Technology Inc.), Apollon, HIF1α, IL8 (Abcam), VEGFα
(Santa Cruz Biotechnology Inc., Dallas, TX, USA), as well as to mouse CD31 (Dianova
GmbH, Hamburg, Germany). The extent of apoptosis in neoplastic nodules was
evaluated by TUNEL staining (Roche). Images were acquired at × 20 with an Axiovert
100 microscope (Zeiss, Oberkochen, Germany) equipped with a digital camera
(AxioCam MrC5, Zeiss).
Statistical analysis. Data from TRAIL susceptibility, TMRE and caspase-8
cleavage assays, as well as the results of drug interaction analyses (combination
index values) were clustered by the Cluster 3.0 software (Tokyo, Japan).
Significance of different treatments on melanoma apoptosis, caspase activation,
mitochondrial depolarization and modulation of apoptosis- and angiogenesis-related
molecules was assessed by ANOVA, followed by the SNK multiple comparison test.
Correlation of melanoma responsiveness to TRAIL with susceptibility to target-
specific inhibitors or with expression of TRAIL receptors were assessed by
Spearman’s correlation analysis. In xenograft experiments, comparison of the anti-
tumor activity of different treatments was carried out by mixed effects model
ANOVA50 by the XLSTAT software (Xlstat, Addinsoft's, New York, NY, USA).
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